These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14511021)

  • 1. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.
    Ugurel S; Lahaye T; Hildenbrand R; Glorer E; Reiter A; Hochhaus A; Schadendorf D; Goerdt S
    Br J Dermatol; 2003 Sep; 149(3):678-9. PubMed ID: 14511021
    [No Abstract]   [Full Text] [Related]  

  • 2. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
    Assouline S; Laneuville P; Gambacorti-Passerini C
    N Engl J Med; 2006 Jun; 354(24):2623-4. PubMed ID: 16775249
    [No Abstract]   [Full Text] [Related]  

  • 3. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
    Ross DM; Jackson SR; Browett PJ
    Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
    [No Abstract]   [Full Text] [Related]  

  • 4. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
    Drummond A; Micallef-Eynaud P; Douglas WS; Hay I; Holyoake TL; Drummond MW
    Br J Haematol; 2003 Mar; 120(5):911-3. PubMed ID: 12614232
    [No Abstract]   [Full Text] [Related]  

  • 5. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
    Fava C; Cortes J
    Am J Hematol; 2008 Sep; 83(9):755. PubMed ID: 18615551
    [No Abstract]   [Full Text] [Related]  

  • 6. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 7. Cocaine abuse may influence the response to imatinib in CML patients.
    Breccia M; Gentilini F; Alimena G
    Haematologica; 2007 Mar; 92(3):e41-2. PubMed ID: 17405756
    [No Abstract]   [Full Text] [Related]  

  • 8. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
    Saavedra D; Vizcarra F
    Leuk Lymphoma; 2014 Dec; 55(12):2813-6. PubMed ID: 24724785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic imatinib: the real-deal or just a deal?
    Mathews V
    Leuk Lymphoma; 2014 Dec; 55(12):2678-80. PubMed ID: 24798742
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
    Mabed M; Elhefni AM; Damnhouri G
    Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 12. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
    Raanani P; Goldman JM; Ben-Bassat I
    J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 14. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
    Georgalas I; Pavesio C; Ezra E
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1585-6. PubMed ID: 17562067
    [No Abstract]   [Full Text] [Related]  

  • 15. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U; Hehlmann R
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract]   [Full Text] [Related]  

  • 16. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
    DeAngelo DJ; Ritz J
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):1-3. PubMed ID: 14734443
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.